Masanori Atsukawa, Akihito Tsubota, Yohei Koushima, Tadashi Ikegami, Kouji Watanabe, Noritomo Shimada, Shinichi Sato, Keizo Kato, Hiroshi Abe, Tomomi Okubo, Taeang Arai, Norio Itokawa, Chisa Kondo, Shigeru Mikami, Toru Asano, Yoshimichi Chuganji, Yasushi Matsuzaki, Katsuhiko Iwakiri
AIM: From a pharmacokinetic viewpoint, the use of ombitasvir/paritaprevir/ritonavir, one of the standards of care for genotype 1b chronic hepatitis C in Japan, could be possible in patients with impaired renal function. The aim of this study was to assess the efficacy and safety of this combination that have not yet been addressed in patients undergoing dialysis. METHODS: A retrospective, multicenter study evaluated the outcome of 12-week ombitasvir (non-structural protein [NS]5A inhibitor)/paritaprevir (NS3/4A protease inhibitor)/ritonavir combination therapy for dialysis patients...
December 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology